Added 17 hours ago Drug news

CHMP recommends Cyltezo (adalimumab biosimilar) to treat multiple chronic inflammatory diseases based on clinical equivalence to Humira (adalimumab), the reference product.- Boehringer.

Boehringer Ingelheim announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has...

Added 6 days ago Drug news

Phase III ARCH study results with Evenity (romosozumab) for osteoporosis published in The New England Journal Of Medicine.- Amgen/UCB.

Amgen and UCB announced detailed results from the Phase III ARCH study showing that 12 months of Evenity (romosozumab) followed...

Added 11 days ago Drug news

SUMMIT-07 Phase III study of NKTR 181, a first-in-class opioid analgesic to treat chronic pain, is presented at the 2017 PAIN Week.- Nektar Therapeutics

Nektar Therapeutics presented clinical data from the SUMMIT-07 Phase III study of NKTR 181, a first-in-class opioid analgesic to treat...

BSR and BHPR guideline on prescribing drugs in pregnancy and breastfeeding—Part II: analgesics and other drugs used in rheumatology practice

The objective of the guideline is to provide evidence-based recommendations, which do not imply a legal obligation, for clinicians to...

Added 1 year ago

BSR and BHPR guideline on prescribing drugs in pregnancy and breastfeeding—Part I: standard and biologic disease modifying anti-rheumatic drugs and corticosteroids

The objective of the guideline is to provide evidence-based recommendations, which do not imply a legal obligation, for clinicians when...

Added 1 year ago

EULAR recommendations for the use of imaging in the diagnosis and management of spondyloarthritis in clinical practice

A taskforce comprised of an expert group of 21 rheumatologists, radiologists and methodologists from 11 countries developed evidence-based recommendations on...

Added 2 years ago

Long-Term Effectiveness of Adalimumab in Patients with Rheumatoid Arthritis: An Observational Analysis from the Corrona Rheumatoid Arthritis Registry.

Introduction: Current recommendations for the management of rheumatoid arthritis (RA) focus on a treat-to-target approach with the objective of maximizing long-term health-related quality-of-life in patients with RA.

Added 6 days ago

Sarilumab: First Global Approval.

Sarilumab (Kevzara™) is a fully human IgG1 monoclonal antibody that binds specifically to both soluble and membrane-bound interleukin (IL)-6 receptors (sIL-6Rα and mIL-6Rα) and thereby inhibits IL-6-mediated...

Added 1 month ago

Sarilumab improves patient-reported outcomes in rheumatoid arthritis patients with inadequate response/intolerance to tumour necrosis factor inhibitors.

Objective: To evaluate effects of the anti-interleukin-6 receptor monoclonal antibody sarilumab administered with conventional synthetic disease-modifying antirheumatic drugs (csDMARDs) on patient-reported outcomes (PROs)...

Added 1 month ago

Inhibition of Co-Stimulation in Rheumatoid Arthritis (ICoSRA)

The purpose of this study is to use abatacept as a clinical molecular probe to evaluate the effects of inhibiting...

Added 2 years ago

A Study Comparing ABT-494 to Placebo and to Adalimumab in Subjects With Rheumatoid Arthritis Who Are on a Stable Dose of Methotrexate and Who Have an Inadequate Response to Methotrexate (SELECT-COMPARE)

This is a phase 3, randomized, double-blind study comparing ABT-494 to Placebo and to Adalimumab in subjects with moderately to...

Added 2 years ago

Efficacy and Safety of Sarilumab and Adalimumab Monotherapy in Patients With Rheumatoid Arthritis (SARIL-RA-MONARCH)

Primary Objective:
- To demonstrate that sarilumab monotherapy is superior to adalimumab monotherapy with respect to signs and symptoms as assessed by disease activity score 28...

Added 3 years ago